Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia

Journal of Clinical Investigation

Volumn 125, Issue 5, 2015, Pages 1857-1872

  Meldi, Kristen ^a   Qin, Tingting ^a   Buchi, Francesca ^b   Droin, Nathalie ^c   Sotzen, Jason ^a   Micol, Jean Baptiste ^c,d   Selimoglu Buet, Dorothée ^c   Masala, Erico ^b   Allione, Bernardino ^e,f   Gioia, Daniela ^f,g   Poloni, Antonella ^f,h   Lunghi, Monia ^f,i   Solary, Eric ^c   Abdel Wahab, Omar ^d   Santini, Valeria ^b,f   Figueroa, Maria E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MOLINETTE HOSPITAL   (Italy)

^f Fondazione Italiana Per le Sindromi Mielodisplastiche (FISM)   (Italy)

^g C Arrigo Children's Hospital   (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; DNA; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; BETA THROMBOGLOBULIN; PPBP PROTEIN, HUMAN; SPACER DNA; THROMBOCYTE FACTOR 4; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; DNA METHYLATION; ENHANCER REGION; EPIGENETICS; FEMALE; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; MALE; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SOMATIC MUTATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BONE MARROW; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; TUMOR GENE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BETA-THROMBOGLOBULIN; BONE MARROW; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, INTERGENIC; DRUG RESISTANCE, NEOPLASM; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PLATELET FACTOR 4; TREATMENT OUTCOME;

EID: 84928982643     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78752     Document Type: Article

References (94)

1. Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Cancer (IARC); 2008.
2. Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
4. Walter MJ, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153-1158.
5. Tefferi A, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN AML. Leukemia. 2009;23(7):1343-1345.
6. Abdel-Wahab O, et al. Genetic characterization of TET1, TET2, TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-147.
7. Gelsi-Boyer V, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788-800.
8. Khan SN, et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia. 2013;27(6):1301-1309.
9. Ernst T, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
10. Makishima H, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24(10):1799-1804.
11. Nikoloski G, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
12. Figueroa ME, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448-3458.
13. Jiang Y, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315-1325.
14. Kantarjian H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
15. Silverman LR, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
16. Ghoshal K, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, nuclear localization signal. Mol Cell Biol. 2005;25(11):4727-4741.
17. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2′- deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res. 2010;38(13):4313-4324.
18. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2′- deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 3B. Mol Cell Biol. 2008;28(2):752-771.
19. Cihak A, Weiss JW, Pitot HC. Effects of 5-azacytidine on hepatic polyribosomes maturation of ribosomal RNA. Acta Biol Med Ger. 1974;33(5-6):859-865.
20. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008;45(1):23-30.
21. Itzykson R, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403-411.
22. Gore SD, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66(12):6361-6369.
23. Daskalakis M, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002;100(8):2957-2964.
24. Kantarjian H, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome chronic myelomonocytic leukemia. Blood. 2007;109(1):52-57.
25. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2′- deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 2005;65(16):7086-7090.
26. Blum W, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884-3891.
27. Shen L, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605-613.
28. Follo MY, et al. Reduction of phospho-inositide- phospholipase C β1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A. 2009;106(39):16811-16816.
29. Issa JP, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635-1640.
30. Fandy TE, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114(13):2764-2773.
31. Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
32. Jankowska AM, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932-3941.
33. Kosmider O, et al. TET2 gene mutation is a frequent adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676-1681.
34. Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
35. Patnaik MM, et al. Spliceosome mutations involving SRSF2, SF3B1, U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, prognostic relevance. Am J Hematol. 2013;88(3):201-206.
36. Bejar R, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705-2712.
37. Traina F, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78-87.
38. Itzykson R, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-1152.
39. Braun T, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118(14):3824-3831.
40. Cheson BD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
41. Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428-2436.
42. Patnaik MM, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations outcomes. Leukemia. 2013;27(7):1504-1510.
43. Meggendorfer M, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120(15):3080-3088.
44. Kohlmann A, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, RUNX1. J Clin Oncol. 2010;28(24):3858-3865.
45. Akalin A, et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 2012;8(6):e1002781.
46. Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
47. Figueroa ME, et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest. 2013;123(7):3099-3111.
48. Bullinger L, et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood. 2010;115(3):636-642.
49. Ehrich M, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;102(44):15785-15790.
50. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature. 2012;489(7414):109-113.
51. Park Y, Figueroa ME, Rozek LS, Sartor MA. MethylSig: a whole genome DNA methylation analysis pipeline. Bioinformatics. 2014;30(17):2414-2422.
52. Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 2013;14(3):R21.
53. Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20(3):273-297.
54. Valencia A, et al. Expression of nucleoside- metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014;28(3):621-628.
55. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
56. Graham SM, Vass JK, Holyoake TL, Graham GJ. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal chronic myeloid leukemia sources. Stem Cells. 2007;25(12):3111-3120.
57. Schaffner A, Rhyn P, Schoedon G, Schaer DJ. Regulated expression of platelet factor 4 in human monocytes - role of PARs as a quantitatively important monocyte activation pathway. J Leukoc Biol. 2005;78(1):202-209.
58. Pillai MM, Iwata M, Awaya N, Graf L, Torok-Storb B. Monocyte-derived CXCL7 peptides in the marrow microenvironment. Blood. 2006;107(9):3520-3526.
59. Bagger FO, et al. HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. Nucleic Acids Res. 2013;41(Database issue):D1034-D1039.
60. Bagger FO, et al. HemaExplorer: a web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis. Blood. 2012;119(26):6394-6395.
61. Aivado M, et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A. 2007;104(4):1307-1312.
62. Chen C, Bowen DT, Giagounidis AA, Schlegelberger B, Haase S, Wright EG. Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q). Leukemia. 2010;24(11):1875-1884.
63. Reikvam H, Fredly H, Kittang AO, Bruserud O. The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine-the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins (Basel). 2013;5(2):336-362.
64. Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud Ø. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol. 2010;341:149-172.
65. Han ZC, et al. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells reduce the chemosensitivity of cells to cytotoxic agents. Blood. 1997;89(7):2328-2335.
66. Gupta SK, Singh JP. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol. 1994;127(4):1121-1127.
67. Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood. 2003;101(12):4687-4694.
68. Bruns I, et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014;20(11):1315-1320.
69. Tsai HC, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430-446.
70. Prebet T, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322-3327.
71. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science. 2002;295(5558):1306-1311.
72. Simonis M, et al. Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C). Nat Genet. 2006;38(11):1348-1354.
73. Zhao Z, et al. Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- interchromosomal interactions. Nat Genet. 2006;38(11):1341-1347.
74. Dostie J, et al. Chromosome Conformation Capture Carbon Copy (5C): a massively parallel solution for mapping interactions between genomic elements. Genome Res. 2006;16(10):1299-1309.
75. Lieberman-Aiden E, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science. 2009;326(5950):289-293.
76. Wong YF, Jakt LM, Nishikawa S. Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies. PLoS One. 2013;8(8):e71099.
77. Chung E, Hsu CL, Kondo M. Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder. PLoS One. 2011;6(12):e28350.
78. Katsoulidis E, et al. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res. 2005;65(19):9029-9037.
79. Abrams SL, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle. 2010;9(9):1781-1791.
80. Steelman LS, et al. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle. 2010;9(8):1629-1638.
81. Zhang L, et al. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014;89(5):499-504.
82. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114-2120.
83. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760.
84. DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-498.
85. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
86. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics. 2011;27(11):1571-1572.
87. RC Team. R: A Language And Environment For Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
88. Gentleman RC, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
89. The Comprehensive R Archive Network. e1071: Misc Functions of the Department of Statistics (e1071), TU Wien. TCRAN Web site. . Accessed February 20, 2015.
90. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics. 2005;21(20):3940-3941.
91. Jiang L, et al. Synthetic spike-in standards for RNA-seq experiments. Genome Res. 2011;21(9):1543-1551.
92. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol. 2013;31(1):46-53.
93. Anders S, Pyl PT, Huber W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166-169.
94. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-140.